Abstract
Progress in individualized diagnosis and therapy for major complex diseases including neuro-developmental and neuro-degenerative medicine, cardiovascular diseases and cancer is relatively slow. The validity of next-generation sequencing (NGS) technologies in identification of genetic heterogeneity-based guided diagnosis advances and challenges are discussed.
Over the past decade, rapid progress in sequencing and characterization of human genome elements in health1 and disease, particularly in cancer2, highlight the shift from inexact medicine to precision personalized medicine. However, with the exception of cancer, accurate individualized risk estimation for major diseases, including metabolic and neurodegenerative disorders, remains challenging3.
(Citation: Gastric & Breast Cancer 2019; 14(1): 1-6)
|
